Fig. 1

Tasquinimod impairs tumor growth in vivo and reduces the microvascular density in MC38-C215 tumors. a Wild type mice were inoculated s.c. with 0.5 × 10⁶ MC38-C215 cells. Treatment with tasquinimod (30 mg/kg ad lib.) was initiated on the day of tumor inoculation and continued throughout the experiment. Tumor volumes (left panel) were measured every 2-3 days from day 7 and the experiment was terminated on day 14 (*p = 0.029; two-way ANOVA, Error bars indicate s.e.m) and tumor weights (right panel) at the end of experiment (*p < 0.05; Mann Whitney). b No effect on MC38-C215 proliferation in vitro. MC38-C215 cancer cells (5000 cells/well) were seeded in 96 well plates and the cultured cells treated with tasquinimod for 72 h under either normoxic (left panel) or hypoxic (right panel) growth conditions. Viability was determined by MTT assay at the end of incubation. c CD31 staining is significantly different between tumors from control and tasquinimod treated animals: Left-control group tumor, right-tasquinimod group tumor. Vascular density determined as percentage of stained area compared to total tumor area (* p < 0.05; Mann Whitney, Error bars indicate s.e.m)